146 related articles for article (PubMed ID: 32324838)
21. Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia.
Capogrosso P; Capitanio U; Vertosick EA; Ventimiglia E; Chierigo F; Oreggia D; Moretti D; Briganti A; Vickers AJ; Montorsi F; Salonia A
Urology; 2018 Dec; 122():152-157. PubMed ID: 30138683
[TBL] [Abstract][Full Text] [Related]
22. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries.
Wong MC; Goggins WB; Wang HH; Fung FD; Leung C; Wong SY; Ng CF; Sung JJ
Eur Urol; 2016 Nov; 70(5):862-874. PubMed ID: 27289567
[TBL] [Abstract][Full Text] [Related]
23. [National prostate cancer registry 2010 in Spain].
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; Cantalapiedra A; Pedrosa E
Actas Urol Esp; 2013 Jan; 37(1):12-9. PubMed ID: 23102541
[TBL] [Abstract][Full Text] [Related]
24. Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015.
Pishgar F; Ebrahimi H; Saeedi Moghaddam S; Fitzmaurice C; Amini E
J Urol; 2018 May; 199(5):1224-1232. PubMed ID: 29129779
[TBL] [Abstract][Full Text] [Related]
25. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
26. [Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014].
Gu XY; Zheng RS; Zhang SW; Zeng HM; Sun KX; Zou XN; Xia CF; Yang ZX; Li H; Chen WQ; He J
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jun; 52(6):586-592. PubMed ID: 29886679
[No Abstract] [Full Text] [Related]
27. Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-alpha-reductase inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a specific region in France.
Scailteux LM; Balusson F; Vincendeau S; Rioux-Leclercq N; Nowak E
Fundam Clin Pharmacol; 2018 Feb; 32(1):120-129. PubMed ID: 28856711
[TBL] [Abstract][Full Text] [Related]
28. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden.
Van Hemelrijck M; Garmo H; Holmberg L; Stattin P; Adolfsson J
Eur Urol; 2012 Apr; 61(4):690-700. PubMed ID: 21945719
[TBL] [Abstract][Full Text] [Related]
29. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014.
Li J; Siegel DA; King JB
Ann Epidemiol; 2018 May; 28(5):328-330. PubMed ID: 29678312
[TBL] [Abstract][Full Text] [Related]
30. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
31. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and Pattern of Mandibular Third Molar Impaction in Eritrean Population: A Retrospective Study.
Kumar VR; Yadav P; Kahsu E; Girkar F; Chakraborty R
J Contemp Dent Pract; 2017 Feb; 18(2):100-106. PubMed ID: 28174361
[TBL] [Abstract][Full Text] [Related]
33. Metformin use and prostate cancer risk.
Preston MA; Riis AH; Ehrenstein V; Breau RH; Batista JL; Olumi AF; Mucci LA; Adami HO; Sørensen HT
Eur Urol; 2014 Dec; 66(6):1012-20. PubMed ID: 24857538
[TBL] [Abstract][Full Text] [Related]
34. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008-2013 from a population-based cancer registry.
Deloumeaux J; Bhakkan B; Eyraud R; Braud F; Manip M'Ebobisse N; Blanchet P; Brureau L
Cancer Causes Control; 2017 Nov; 28(11):1265-1273. PubMed ID: 28921374
[TBL] [Abstract][Full Text] [Related]
36. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics.
Pakzad R; Rafiemanesh H; Ghoncheh M; Sarmad A; Salehiniya H; Hosseini S; Sepehri Z; Afshari-Moghadam A
Asian Pac J Cancer Prev; 2016; 17(2):839-43. PubMed ID: 26925689
[TBL] [Abstract][Full Text] [Related]
37. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer trends in Latvia during 1990-2012: incidence, prevalence, mortality, and survival rates.
Plonis J; Bokums K; Cauce V; Miklasevics E; Vaganovs P; Irmejs A; Gardovskis J; Vjaters E
Medicina (Kaunas); 2014; 50(6):313-7. PubMed ID: 25541262
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer incidence and mortality trends among elderly and adult Europeans.
Vercelli M; Quaglia A; Marani E; Parodi S
Crit Rev Oncol Hematol; 2000 Aug; 35(2):133-44. PubMed ID: 10936470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
